Laborate Pharmaceuticals’ Aqualab hits Rs 100 crore in revenue, targets Rs 250 crore next

Aqualab, the direct-to-retail division of Laborate Pharmaceuticals India Ltd, has crossed the Rs 100 crore revenue mark within three years of launch and now expects to touch Rs 250 crore by FY 25-26.

Advertisment

The company said the growth has been driven by an expanding portfolio of over 800 SKUs and a network of 500+ retail stockists, with tier-II and tier-III markets contributing a rising share of sales.

Since its inception in 2022, the division has reported consistent year-on-year growth, moving from Rs 76 crore in FY 2022-23 to Rs 108 crore in FY 2023-24.  Aqualab said it has focused on ensuring affordability and last-mile access, enabling its medicines to reach smaller towns alongside metropolitan centres.

“Crossing Rs 100 crore in three years demonstrates how quickly the Direct-to-Retail model is scaling in India. We are now targeting Rs 250 crore by FY 25–26, with non-metro markets expected to contribute 42% of incremental growth. Expanding therapeutic categories and strengthening last-mile delivery will remain our key focus areas,” said Arpit Bhatia, Managing Director, Laborate Pharmaceuticals.

The company further said that its growth aligns with national priorities such as Make in India and the government’s PLI push to boost domestic pharma manufacturing.

The retail pharmacy market, pegged at Rs 18,700 crore in FY24, is projected to touch Rs 31,200 crore by FY32, growing at a CAGR of 6.6% on the back of stronger generic penetration, greater health awareness, and organised distribution. Leveraging this growth, Aqualab is preparing to expand into new categories, add facilities, adopt digital channels, and explore exports, consolidating its position in India’s retail pharma landscape.

Laborate’s WHO, GMP, and EU GMP-certified facilities have provided Aqualab with the infrastructure to scale rapidly while maintaining international quality standards. The company operates modern plants with advanced manufacturing and quality control systems, enabling compliance with stringent benchmarks. This foundation has not only supported Aqualab’s domestic expansion but also positions the division for potential export opportunities in the future.